Sherwood News

What’s eating Novo Nordisk?

The Ozempic maker’s market cap has more than halved since this time last year.

7/30/25 9:26AM

Last July, Novo Nordisk, the drugmaker that brought us Ozempic and Wegovy, was sitting pretty as Europe’s most valuable company — and, with a margin of more than $200 billion between it and storied luxury house LVMH, it wasn’t even really close. A lot can change in a year.

Weighed down

Since peaking just shy of $660 billion last summer, Novo has been shedding market cap almost nonstop. Yesterday, shares ended up posting their steepest single-day drop in the Danish behemoth’s history, sliding 23% after the company slashed its sales and profit outlook for the year ahead. Now, Novo’s new CEO, a veteran insider who was announced with the slimmed-down outlook yesterday, will have his work cut out to stop the bleeding.

If 2024 was the year that GLP-1s “took over,” Ozempic (launched in the US in 2017) was very much leading the charge, having amassed enough cultural weight to serve as the poster child for the new wave of obesity treatments.

Since then, however, offerings from Eli Lilly, as well as stiff competition from compounders like Hims & Hers and Noom, have started to muscle in on Novo’s leading Ozempic and Wegovy drugs. Notably, Lilly’s Mounjaro and Zepbound have proven to be more effective for weight loss with fewer side effects, according to reporting from the Financial Times.

Nouveau problems

Much is made of first-mover advantage in business, but Novo might just be the latest in a long list of cautionary tales — MySpace, BlackBerry, Yahoo Search, Zoom, Peloton — that proves being early isn’t always enough. With new GLP-1 effort CagriSema disappointing across trials in December and March, it’s not just Novo that’s feeling the pain; the company’s slumping sales are hurting Denmark’s national export figures, too.

Go Deeper: How the Novo Nordisk-Hims & Hers partnership epically flopped in just two months | Is Ozempic old news?

Nia Warfield, Luke Kawa

S&P 500 goes nowhere, Nasdaq 100 hits another record, small-caps tumble

Warner Bros. Discovery led gains for the second day in a row, and only three S&P 500 sector ETFs finished in the green.

Matt Phillips

Rocket lab soars to new record close amid rally for retail faves

Rocket Lab ripped by roughly 10% Friday to close at a new all-time high, riding an upturn of retail enthusiasm for a coterie of tech-themed favorites, even as the broader market was more or less flat on the day.

Goldman Sachs’ basket of “retail favorites” — its heaviest weights are Reddit, AppLovin, and Tempus AI — was the second-biggest gainer among the company’s flagship US equity baskets on Friday, rising about 1.6%. The S&P was almost dead flat.

It’s not Rocket Lab’s first retail rodeo, as the money-losing company has more than doubled this year and is up nearly 700% over the last 12 months.

Analysts revise up anything and everything they thought about Oracle

After the company’s bombshell earnings this week, Wall Street thinks Oracle’s trajectory has changed.

Matt Phillips8h

Nia Warfield

Six Flags pops after reiterating its guidance as theme park attendance rebounds

Six Flags shares rose more than 7% today after the company reported a rebound in attendance and early season pass sales heading into the fall. The nine-week period ended August 31 saw 17.8 million guests, up about 2% from the same stretch last year, with stronger momentum in the final four weeks.

More importantly, Six Flags reaffirmed its full-year adjusted EBITDA guidance of $860 million to $910 million, showing confidence that its cost and operations strategy can stay strong for the duration of the year. Riding that wave, Six Flags also said early 2026 season pass unit sales are pacing ahead of last year, and average season pass prices are up about 3%.

The good vibes come despite a drop in in-park per-capita spending, especially from admissions, where promotions and changes to attendance mix (which parks or days guests visit) have weighed. Earlier this week, the amusement giant signed a new agreement that extended its position as the exclusive amusement park partner for Peanuts™ in North America through 2030.

Despite the rally, Six Flags shares are down about 52% year to date.

Max Knoblauch

11h

Rivian turns red on the year, squeezed by a recall and the looming end of the EV tax credit

Shares of EV maker Rivian are down more than 5% on Friday following the company’s recall of 24,214 vehicles due to a software issue. The stock move erases Rivian’s year-to-date gain and turns the company negative on the year.

Rivian’s 2025 model year R1S and R1T are affected by the defect, which was identified after a vehicle’s hands-free highway assist software failed to identify another vehicle on the road, causing a low-speed collision. Rivian said it’s released an over-the-air update to fix the issue.

The recall marks Rivian’s fifth this year, affecting nearly 70,000 of its vehicles.

Rivian’s shares are down more than 20% from their 2025 high, which came prior to the passage of President Trump’s “big, beautiful bill.” Through the legislation, the $7,500 EV tax credit is set to expire at the end of the month.